PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company focused on personalized medicines, today announced the establishment of PERSONALIZ3D™, an integrated ecosystem that will combine telehealth, pharmaceutical 3D printing, and pharmacy fulfillment to support the delivery of personalized medicines. PERSONALIZ3D™ expands PharmaTher's previously announced Personaliz3D P
Biotechnology, Pharmaceuticals
2026-08-11 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) -
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:30 AM EDT | BioHarvest Sciences Inc.
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences I
Biotechnology, Pharmaceuticals, Health
2026-08-11 6:00 AM EDT | BioHarvest Sciences Inc.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Theralase(R) Announces $5 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Age
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-10 5:15 PM EDT | Theralase Technologies Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on Friday, August 14th, at 11:30 AM EDT to discuss the company's financial and o
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 4:54 PM EDT | Elite Pharmaceuticals, Inc.
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible par
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-07 5:25 PM EDT | Theralase Technologies Inc.
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today reported financial results for the second quarter ended June 30, 2026, and provided an update on its clinical pipeline of small-molecule therapies for retinal diseases and its corporate development activities. Second Quarter 2026 and Recent Highlights Advanced enrollment in the Phase 2 ABACUS-2 clinical trial of KIO-301 into the higher-dose cohort
Biotechnology, Pharmaceuticals
2026-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Extendicare Announces 2026 Second Quarter Results
Markham, Ontario--(Newsfile Corp. - August 6, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") today reported results for the three and six months ended June 30, 2026. Second Quarter 2026 Highlights Adjusted EBITDA(1) increased by $28.5 million or 71.7% from Q2 2025 to $68.3 million, driven primarily by contributions from the acquisitions of CBI Home Health and Closing the Gap, as well as continued
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 5:00 PM EDT | Extendicare Inc.
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminat
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 4:05 PM EDT | Phio Pharmaceuticals Corp.
Jones Healthcare Group Expands Integrated Packaging Capabilities With Thermoforming Acquisition
London, Ontario--(Newsfile Corp. - August 6, 2026) - Jones Healthcare Group has acquired an operating thermoforming facility and related business assets in Brampton, Ont., adding in-house production of custom-formed packaging components to its integrated offering. The acquisition includes the facility, equipment and an experienced team of colleagues who will join Jones Healthcare. The addition complements the company's existing expertise in printed packaging components, contract packagi
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 10:30 AM EDT | Jones Healthcare Group
Joseph N. Savasta Named 2026 PBMI Innovator Award Recipient
New York, New York--(Newsfile Corp. - August 6, 2026) - HarmonyRx is proud to announce that its Chief Executive Officer, Joseph N. Savasta, has been selected as a recipient of the 2026 PBMI Innovator Award, presented by the Pharmacy Benefit Management Institute (PBMI) and Managed Healthcare Executive. The PBMI Innovator Award recognizes individuals who are driving meaningful change within the pharmacy benefits industry through innovation, leadership and a commitment to imp
2026-08-06 9:10 AM EDT | HarmonyRx
NuGen Announces Non-Binding LOI to Acquire Sol-Millennium Canada
Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce it has entered a non-binding letter of intent ("LOI") with Sol-Millennium Medical HK Limited ("SolM HK"), the sole shareholder of Sol-Millenium Canada Inc. ("SolM"), dated August 5, 2026 to acquire all of the issued and outstanding common shares of SolM (the "Proposed Transaction"). Each party is curre
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 8:07 AM EDT | NuGen Medical Devices Inc.
Custom Health to Acquire Spencer Health Solutions, Strengthening Its Medication Management Infrastructure at Home
Custom Health has entered into a definitive agreement to acquire Spencer Health Solutions, which is expected to unite Custom Health's pharmacist-led medication management platform with the spencer® in-home smart dispensing and monitoring system, bringing an important in-home medication technology capability fully in-house and further strengthening Custom Health's medication management at home. The Transaction is expected to expand the Corporation's margins by elimi
Technology, Pharmaceuticals, Health
2026-08-05 6:00 AM EDT | Custom Health Holdings Inc.
PreveCeutical Closes Fourth Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated July 27, 2026, June 12, 2026, May 12, 2026 and April 22, 2026 (the "Prior News Releases"), it has closed a fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Offering"),
Biotechnology, Pharmaceuticals, Health
2026-08-04 5:20 PM EDT | PreveCeutical Medical Inc.
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat P
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-04 7:00 AM EDT | Elite Pharmaceuticals, Inc.
TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a strategic partnership with Stealth Health (stealth.health), a leading telemedicine platform for longevity and precision wellness in North America. The agreement integrates TempraMed's VIVI product portfolio into
Technology, Biotechnology, Pharmaceuticals, Health
2026-08-04 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-04 7:00 AM EDT | Theralase Technologies Inc.
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Montreal, Quebec--(Newsfile Corp. - August 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026. As part of the leadership transitio
Biotechnology, Pharmaceuticals, Health
2026-08-04 3:15 AM EDT | Defence Therapeutics Inc.